Literature DB >> 17102629

Apoptosis in activated T cells: what are the triggers, and what the signal transducers?

Georg Häcker1, Anette Bauer, Andreas Villunger.   

Abstract

At the end of an immune response, apoptosis drastically reduces the numbers of activated T cells. It has been a matter of intense research how this form of apoptosis is regulated and initiated, and a number of proteins have been identified that contribute to this process. The present, widely accepted model assumes that the interplay of pro- and anti -apoptotic Bcl-2 family members determines the onset of activated T cell death, with the BH3-only protein Bim activating pro-apoptotic Bax/Bak. In the search for up-stream signals, factors from other immune cells have been shown to play a role, and the NFkappaB family member Bcl-3 has been implicated as a signalling-intermediate in T cells. Recent work has tested the interrelation of these factors and has suggested that Bcl-3 acts as a regulator of Bim activation, that the induction of apoptosis through Bim can be complemented by its relative Puma, and that the presence of certain cytokines during T cell activation delays the activation of Bim and Puma. Here we discuss these recent insights and provide a view on how the regulation of activated T cell death is achieved and how extrinsic signals may translate into the activation of the apoptotic pathway.

Mesh:

Substances:

Year:  2006        PMID: 17102629     DOI: 10.4161/cc.5.21.3397

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  18 in total

1.  Exploring regulatory mechanisms of CD8+ T cell contraction.

Authors:  Martin Prlic; Michael J Bevan
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-22       Impact factor: 11.205

Review 2.  Programmed necrosis and autophagy in immune function.

Authors:  Jennifer V Lu; Craig M Walsh
Journal:  Immunol Rev       Date:  2012-09       Impact factor: 12.988

3.  Protein phosphatase 2A B55β limits CD8+ T cell lifespan following cytokine withdrawal.

Authors:  Noé Rodríguez-Rodríguez; Iris K Madera-Salcedo; J Alejandro Cisneros-Segura; H Benjamín García-González; Sokratis A Apostolidis; Abril Saint-Martin; Marcela Esquivel-Velázquez; Tran Nguyen; Dámaris P Romero-Rodríguez; George C Tsokos; Jorge Alcocer-Varela; Florencia Rosetti; José C Crispín
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

Review 4.  Activation-induced cell death in CAR-T cell therapy.

Authors:  Tian Huan; Dongfeng Chen; Guodong Liu; Hailing Zhang; Xiaoyan Wang; Zhi Wu; Yan Wu; Qinggang Xu; Feng Yu
Journal:  Hum Cell       Date:  2022-01-15       Impact factor: 4.174

5.  Cell cycle progression following naive T cell activation is independent of Jak3/common gamma-chain cytokine signals.

Authors:  Min Shi; Tsung H Lin; Kenneth C Appell; Leslie J Berg
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

6.  Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy.

Authors:  Grégory Verdeil; Kristi Marquardt; Charles D Surh; Linda A Sherman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-20       Impact factor: 11.205

7.  Loss of the death receptor CD95 (Fas) expression by dendritic cells protects from a chronic viral infection.

Authors:  Vineeth Varanasi; Aly Azeem Khan; Alexander V Chervonsky
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-27       Impact factor: 11.205

8.  The stress-response factor SigH modulates the interaction between Mycobacterium tuberculosis and host phagocytes.

Authors:  Noton K Dutta; Smriti Mehra; Alejandra N Martinez; Xavier Alvarez; Nicole A Renner; Lisa A Morici; Bapi Pahar; Andrew G Maclean; Andrew A Lackner; Deepak Kaushal
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

9.  GIMAP Proteins in T-Lymphocytes.

Authors:  Sanna Filén; Riitta Lahesmaa
Journal:  J Signal Transduct       Date:  2010-08-31

10.  Hemagglutinin from the H5N1 virus activates Janus kinase 3 to dysregulate innate immunity.

Authors:  Wei Xu; Minhui Chen; Nanhai Ge; Jun Xu
Journal:  PLoS One       Date:  2012-02-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.